Grandbrothers The U.S. FDA has cleared Zymeworks' ( NASDAQ: ZYME ) Investigational New Drug application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.
On its website, the company said that MSLN is expressed in many different types of cancer, including pancreatic, colorectal and ovarian. Zymeworks plans to start a phase 1 study this year. More on Zymeworks Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data Zymeworks shares sink after company removes CFO Christopher Astle Zymeworks Inc.
(ZYME) Q1 2024 Earnings Call Transcript Zymeworks Q1 2024 Earnings Preview Seeking Alpha's Quant Rating on Zymeworks.
